Top

The European Journal of Health Economics

Published in:

01-11-2004 | Pricing and reimbursement

Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden

The first year

Authors: Joakim Ramsberg, Stefan Odeberg, Andreas Engström, Douglas Lundin

Published in: The European Journal of Health Economics | Issue 4/2004

Abstract

This study assessed the quality of health economic documentation submitted to the Pharmaceutical Benefits Board (PBB) in Sweden. Two different instruments were used in the evaluation: the PBB checklist, which was constructed by the authors from the PBB guidelines for health economic evaluations, and the QHES, a validated quality assessment instrument. Some areas that seem especially problematic, or where the quality was particularly low are identified and discussed. Also, we present the cost per quality-adjusted life-year that the companies have presented and how this related to the PBBs decisions.

Available only for authorised users

Bradley CA, Iskedjian M, Lancot KL et al. (1995) Quality assessment of economic evaluations in selected pharmacy, medical and health economics journals. Ann Pharmacother 29:681–689PubMed

Kumar, Ritesh N, Raisch, Dennis W, Borrego, Matthew E (2002) Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia. Expert Rev Pharmacoecon Outcomes Res 2:565–575

Iskedjian M, Trakas K, Bradley CA et al. (1997) Quality assessment of economic evaluations published in pharmacoeconomics. Pharmacoeconomics 12:685–694PubMed

Baladi J-F, Menon D, Otten N (1998) Use of economic evaluation guidelines: 2 years’ experience in Canada. Health Econ 7:221–227CrossRefPubMed

Anis AH, Gagnon Y (2000) Using economic evaluations to make formulary coverage decisions: so much for guidelines. Pharmacoeconomics 18:55–62PubMed

Hill SR, Mitchell AS, Henry DA (2000) Problems with the interpretation of pharmaeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2116–21

Pharmaceutical Benefits Board (2003) General guidelines for economic evaluations from the Pharmaceuticals Benefits Board. LFNAR 2003, 2. Available athttp://www.lfn.se/documents/In%20English/ENG_lfnar2003-eng.pdf. Accessed November 18

Ofman, Joshua J, Sullivan, Sean D, Neumann, Peter J, Chiou, Chiun-Fang, Henning, James M, Wade, Sally W, Hay JW (2003) Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Managed Care Pharm 9:53–61

Philips Z, Ginelly L, Sculpher M, Claxton K (2003) A review of guidelines for good practice in decision-analytic modelling in health technology assessment. Presented at the Society for Medical Decision Making, 25th annual meeting. October , Chicago

Title: Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden
The first year
Authors: Joakim Ramsberg
Stefan Odeberg
Andreas Engström
Douglas Lundin
Publication date: 01-11-2004
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 4/2004
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-004-0246-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden

The first year

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2004

Exponential health utility

Approval times and the safety of new pharmaceuticals

Re-scaling social preference data: implications for modelling

Willingness to pay for dental fear treatment

What reimbursement for coronary revascularization with drug-eluting stents?

The high cost of medicines in Ireland